Tag: brian tumours
No posts to display
News
CARVYKTI becomes first BCMA-targeted treatment approved by European Commission for patients with relapsed and...
The European Commission (EC) has approved a Type II variation for Janssen-Cilag International NV's (a Johnson & Johnson company) CARVYKTI (ciltacabtagene autoleucel; cilta-cel).
This latest...
Evotec and Variant Bio to discover and develop fibrosis treatments
Evotec and Variant Bio have announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
Fibrosis is characterised by marked and...
Takeda, Astellas and Sumitomo Mitsui Banking to establish joint venture company for incubation of...
Takeda, Astellas, and Sumitomo Mitsui Banking Corporation (SMBC) have signed a master agreement to establish a joint venture company. The new company will be...
